Influenza Research and Treatment
Volume 2011 (2011), Article ID 759051, 8 pages
doi:10.1155/2011/759051
Clinical Study

Efficacy and Safety of CVT-E002, a Proprietary Extract of Panax quinquefolius in the Prevention of Respiratory Infections in Influenza-Vaccinated Community-Dwelling Adults: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial

Janet E. McElhaney,1 Andrew E. Simor,2 Shelly McNeil,3 and Gerald N. Predy4

1UBC Gerontology and Diabetes Research, 186-828 West 10th Avenue, Vancouver, BC, V5Z 1L8, Canada
2Department of Microbiology, Sunnybrook and Women's College Health Sciences Center, Toronto, QN, M4N 3M5, Canada
3Clinical Trials Research Center, IWK Health Center, 5850/5980 University Avenue, Halifax, NS, B3K 6R8, Canada
4Capital Health, Alberta Health Services, Suite 300, 10216-124 Street, Edmonton, AB, T5N 4A3, Canada

Received 5 February 2011; Revised 16 May 2011; Accepted 19 May 2011

Academic Editor: Oleg P. Zhirnov

Copyright © 2011 Janet E. McElhaney et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Janet E. McElhaney, Andrew E. Simor, Shelly McNeil, and Gerald N. Predy, “Efficacy and Safety of CVT-E002, a Proprietary Extract of Panax quinquefolius in the Prevention of Respiratory Infections in Influenza-Vaccinated Community-Dwelling Adults: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial,” Influenza Research and Treatment, vol. 2011, Article ID 759051, 8 pages, 2011. doi:10.1155/2011/759051